Techcyte provides a unified, AI-powered digital pathology platform that streamlines complex workflows, integrates with core lab systems, and enhances communication across the lab. The company partners with laboratories, scanner manufacturers, diagnostic hardware providers, and AI developers to deliver its platform to labs and clinics globally. Techcyte's veterinary business is currently profitable, and the company expects its environmental and human segments to reach profitability by next year. It is led by CEO Ben Cahoon and is headquartered in Orem, Utah. Techcyte announced it will deploy the newly raised capital to execute strategic priorities and support its path to profitability. The articles do not disclose revenue, user counts, or prior funding amounts.

Total raised

$40M

Funding rounds

3

Latest round

Equity

Latest activity

May 2026